Evidence map›Paper›PMID 32991246›Full record

ReviewJournal of women's health (2002)2021

The Masquerading, Masculinizing Tumor: A Case Report and Review of the Literature.

Alexis LeVee, Nissi Suppogu, Christine Walsh, Wendy Sacks, James Simon, Chrisandra Shufelt

Open access · greenAbstract readCase ReportsReview
In one paragraph

Review in Journal of women's health (2002), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Non-PCOS Hyperandrogenic Disorders in Adolescents.Seminars in reproductive medicine · 2022
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Alexis LeVeeDepartment of Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Nissi SuppoguBarbra Streisand Women's Heart Center, Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, California, USA.
Christine WalshDepartment of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Wendy SacksDepartment of Endocrinology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
James SimonIntimMedicine Specialists, Department of Obstetrics and Gynecology, George Washington University School of Medicine, Washington, District of Columbia, USA.
Chrisandra ShufeltBarbra Streisand Women's Heart Center, Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, California, USA.
Cedars-Sinai Medical Center · USGeorge Washington University · US

Funding

Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young WomenK23HL127262 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI SHUFELT, CHRISANDRA LEE · 2016 to 2020
$988k
NHLBI NIH HHS K23 HL127262
6 · The paper itself

Abstract

Androgen-producing tumors in women are rare neoplasms that can cause secondary virilizing characteristics. Of patients presenting with symptoms of hyperandrogenism, these tumors are found in ∼0.2% of cases. Androgen-producing tumors can arise from the ovary or the adrenal gland. Those arising from the ovary are rare, accounting for <5% of all ovarian tumors. This case presents a hilar Leydig cell tumor of the ovary, which resulted in secondary virilization of a 45-year-old female 2 months after cessation of combined oral contraceptives (COC). Laboratory findings showed markedly elevated total and free testosterone concentrations with normal dehydroepiandrosterone sulfate, however neither pelvic ultrasound nor magnetic resonance imaging demonstrated any masses. Venous sampling under fluoroscopy revealed supraphysiologic testosterone concentrations from the right ovarian vein suggesting the source. The patient underwent bilateral salpingo-oophorectomy revealing a 1.3 cm hilar cell tumor of the right ovary. This article reviews the clinical features, diagnosis, and treatment of hilar Leydig cell tumors and describes the long-term complications of supraphysiologic testosterone levels. As the tumor presented after cessation of COC, we also review the mechanisms by which COC might suppress supraphysiologic androgen levels and mask the secondary virilizing effects of androgen-producing tumors.

Indexed as

HyperandrogenismLeydig Cell TumorOvarian NeoplasmsFemaleHumansMaleMiddle AgedOvaryTestosteroneUltrasonographyVirilismTestosteronecombined oral contraceptiveHILAR cell tumorLeydig celltestosteronevirilization

Identifiers

PMID32991246
PMCPMC8290302
OpenAlexW3091239355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.